Substance / Medication

Human antithrombin III

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Anti-viral activity of human antithrombin III.
Elmaleh David R, Brown Nancy V, Geiben-Lynn Ralf · Int J Mol Med · 2005
PMID: 16012749Observational
Expression and characterization of recombinant human antithrombin III in Pichia pastoris.
Mochizuki S, Hamato N, Hirose M et al. · Protein Expr Purif · 2001
PMID: 11570846Observational
Recombinant human antithrombin III: rhATIII.
Drugs R D · 2004
PMID: 15293873Review
Pharmacokinetics of human antithrombin III concentrate in the immediate postoperative period after liver transplantation.
Kim Bo Rim, Oh Jaeseong, Yu Kyung-Sang et al. · Br J Clin Pharmacol · 2020
PMID: 31840271OtherFull text (PMC)
[Purification of recombinant human antithrombin III expressed in a goat mammary bioreactor].
Wang Cuijie, Huang Yongdong, Kong Yingjun et al. · Sheng Wu Gong Cheng Xue Bao · 2014
PMID: 25726588Preclinical
Antimicrobial effects of helix D-derived peptides of human antithrombin III.
Papareddy Praveen, Kalle Martina, Bhongir Ravi K V et al. · J Biol Chem · 2014
PMID: 25202017PreclinicalFull text (PMC)
Overexpression of GADD34 enhances production of recombinant human antithrombin III in Chinese hamster ovary cells.
Omasa Takeshi, Takami Takashi, Ohya Tomoshi et al. · J Biosci Bioeng · 2008
PMID: 19134553Preclinical
Improved production of recombinant human antithrombin III in Chinese hamster ovary cells by ATF4 overexpression.
Ohya Tomoshi, Hayashi Tetsuji, Kiyama Eriko et al. · Biotechnol Bioeng · 2008
PMID: 18078289Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Human antithrombin III (substance)
SNOMED CT
412564003
UMLS CUI
C0724532

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.